In addition to reporting 2024 revenue at the lower end of its previous guided range, Moderna issued a disappointing forward ...
Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...
In that vein, let's learn about the three most important things you should know if you're going to consider investing in ...
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...
Moderna’s mRESVIA is the first FDA-approved mRNA therapy designed to prevent respiratory syncytial virus (RSV) in adults 60 and over. The EU, Norway, Iceland, and Qatar have also approved it.
Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.
The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased ...
Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...
Through the first nine months of 2024, Moderna's revenue of $2.3 billion represents a 44% decline year over year. This figure includes a mere $10 million in sales of the new RSV vaccine following ...